Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients
- Resource Type
- article
- Authors
- Yu-Chi Chang; Bang-Gee Hsu; Hung-Hsiang Liou; Chung-Jen Lee; Ji-Hung Wang
- Source
- BMC Cardiovascular Disorders, Vol 18, Iss 1, Pp 1-8 (2018)
- Subject
- Arterial stiffness
Carotid–femoral pulse wave velocity
Hypertension
Sclerostin
Dickkopf-1
Diseases of the circulatory (Cardiovascular) system
RC666-701
- Language
- English
- ISSN
- 1471-2261
Abstract Background Sclerostin is known to be a canonical Wnt/β-catenin signaling pathway inhibitor, while the Wnt/β-catenin signaling pathway is proposed to be involved in the development of arterial stiffness. This study aims to investigate the relationship between serum sclerostin levels and carotid–femoral pulse wave velocity (cfPWV) among hypertensive patients. Methods Fasting blood samples were obtained from 105 hypertensive patients. Patients with cfPWV values of > 10 m/s were classified in the high arterial stiffness group, whereas those with cfPWV values of ≤10 m/s were assigned to the low arterial stiffness group. Serum sclerostin and Dickkopf-1 (DKK1) levels were quantified using commercially available enzyme-linked immunosorbent assays. Results Thirty-six hypertensive patients (34.3%) who belonged to the high arterial stiffness group were generally older (p